These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 11158619

  • 1. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
    Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M.
    Proc Natl Acad Sci U S A; 2001 Jan 30; 98(3):1212-7. PubMed ID: 11158619
    [Abstract] [Full Text] [Related]

  • 2. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.
    Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y.
    J Med Chem; 2004 Sep 23; 47(20):4897-904. PubMed ID: 15369394
    [Abstract] [Full Text] [Related]

  • 3. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.
    Gershonov E, Goldwaser I, Fridkin M, Shechter Y.
    J Med Chem; 2000 Jun 29; 43(13):2530-7. PubMed ID: 10891112
    [Abstract] [Full Text] [Related]

  • 4. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 29; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 5. N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C(1) is a long-acting prodrug derivative.
    Shechter Y, Tsubery H, Fridkin M.
    J Med Chem; 2002 Sep 12; 45(19):4264-70. PubMed ID: 12213067
    [Abstract] [Full Text] [Related]

  • 6. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
    Sasson K, Marcus Y, Lev-Goldman V, Rubinraut S, Fridkin M, Shechter Y.
    J Control Release; 2010 Mar 03; 142(2):214-20. PubMed ID: 19883707
    [Abstract] [Full Text] [Related]

  • 7. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM.
    Antivir Ther; 2006 Mar 03; 11(1):35-45. PubMed ID: 16518958
    [Abstract] [Full Text] [Related]

  • 8. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.
    Pan M, Kalie E, Scaglione BJ, Raveche ES, Schreiber G, Langer JA.
    Biochemistry; 2008 Nov 18; 47(46):12018-27. PubMed ID: 18937499
    [Abstract] [Full Text] [Related]

  • 9. [2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.
    Shechter Y, Tsubery H, Fridkin M.
    Biochem Biophys Res Commun; 2003 May 30; 305(2):386-91. PubMed ID: 12745087
    [Abstract] [Full Text] [Related]

  • 10. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.
    Bioconjug Chem; 2006 May 30; 17(1):179-88. PubMed ID: 16417267
    [Abstract] [Full Text] [Related]

  • 11. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
    Stancek D, Fuchsberger N, Oltman M, Schmeisser H, Kontsek P, Jahnová E, Hajnická V.
    Acta Virol; 2001 May 30; 45(5-6):287-92. PubMed ID: 12083327
    [Abstract] [Full Text] [Related]

  • 12. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application.
    King M, Kumar P, Michel D, Batta R, Foldvari M.
    Eur J Pharm Biopharm; 2013 Aug 30; 84(3):532-9. PubMed ID: 23500117
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE.
    Antiviral Res; 2005 Jan 30; 65(1):23-34. PubMed ID: 15652968
    [Abstract] [Full Text] [Related]

  • 14. Engineered acid-stabile human interferon gamma.
    Kontsek P, Waschütza G, Kontseková E, Otto B.
    Cytokine; 2000 Jun 30; 12(6):708-10. PubMed ID: 10843749
    [Abstract] [Full Text] [Related]

  • 15. The biological effects of five feline IFN-alpha subtypes.
    Baldwin SL, Powell TD, Sellins KS, Radecki SV, Cohen JJ, Milhausen MJ.
    Vet Immunol Immunopathol; 2004 Jun 30; 99(3-4):153-67. PubMed ID: 15135982
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
    Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C.
    J Pharmacol Exp Ther; 2002 Nov 30; 303(2):540-8. PubMed ID: 12388634
    [Abstract] [Full Text] [Related]

  • 17. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
    Yuan L, Wang J, Shen WC.
    J Control Release; 2008 Jul 02; 129(1):11-7. PubMed ID: 18448186
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
    Santodonato L, Ferrantini M, Palombo F, Aurisicchio L, Delmastro P, La Monica N, Di Marco S, Ciliberto G, Du MX, Taylor MW, Belardelli F.
    Cancer Gene Ther; 2001 Jan 02; 8(1):63-72. PubMed ID: 11219495
    [Abstract] [Full Text] [Related]

  • 19. ELISA measurement of interferons.
    Garrison TL, Hung F, Izotova L, Schwartz B, Lavoie T, Lee-Own FV.
    Biotechniques; 2002 Oct 02; Suppl():98-100. PubMed ID: 12395933
    [No Abstract] [Full Text] [Related]

  • 20. Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli.
    Ooi EL, Verjan N, Hirono I, Nochi T, Kondo H, Aoki T, Kiyono H, Yuki Y.
    Fish Shellfish Immunol; 2008 May 02; 24(5):506-13. PubMed ID: 18329900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.